A few weeks ago, Ronald Vos and Nutte van Belzen, the founders of CC Diagnostics were at a major European medical congress when they were approached by a woman who didn’t work in science or medicine. She had bought an expensive delegate ticket, not to participate in the conference, but to seek help.
She had advanced cervical cancer. And she came in the hope that someone…anyone, at this gathering of gynaecologists and scientists might listen to her story and offer a lifeline.
“We hope all those cases can be prevented,” co-founder Nutte van Belzen reflects.
That moment captures exactly why this episode matters.
Only 15% of women participate in cervical screenings, despite the fact that cervical cancer is entirely preventable through early detection and vaccination.
The problem?
Existing methods are invasive, uncomfortable, and all too easy to avoid until it’s too late.
In this conversation, the founders of CC Diagnostics share their journey: the personal experience and passion that fuels their mission, the technology they are building to make self-sampling accessible, and their vision for a world where diagnostics are not a privilege, but a right.
We also dive into:
The overlooked challenges of building a diagnostics company.
Why many investors hesitate and why that needs to change.
Their roadmap for global access, including a pricing model for low- and middle-income countries (LMICs).
This isn’t just a conversation about tech or start-ups.
It’s about the human stories that push innovation forward, and the urgent need to act before another woman buys a ticket to beg for care.
🎧 Watch the full episode for a powerful and personal look at how we can, and must, do better in women’s health.
CC Diagnostics
CC Diagnostics (Netherlands) offers a clinically validated screening test, significantly improving cervical cancer detection rates to 97% (vs current market benchmark of 76%). Our product offers a 6x reduction in time per test for the diagnostic labs, dramatically reducing costs and improving efficiency. Our Methica test technology enables screening from home (with self-sampled material), unlocking a broader €5.5Bn screening market worldwide. We achieved commercial progress, with the first 2 international orders from leading CLIA labs in the US and UK.
🛠️ Producing stories like this takes time, care, and independent support. If you’d like to help power this work through a small donation or by partnering on the podcast here’s how. Every bit helps amplify the founders shaping the future of women’s health.
📢 Know someone who cares about women's health, mental health, or the future of work? Share this with them.
Let’s keep the conversation going.
#WomensHealth #FemTech #PatientCapital
💬 If this resonated, hit ❤️ or 🔄 to help others find it.
Share this post